[{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"e994ddd8-c8c2-48db-9917-ca57ceffe9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04995185","created_at":"2021-08-06T12:53:11.830Z","updated_at":"2024-07-02T16:35:03.536Z","phase":"","brief_title":"18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study","source_id_and_acronym":"NCT04995185","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" HIF1A • CA9","pipe":" | ","alterations":" HIF1A expression • VEGFA expression • CA9 expression","tags":["HIF1A • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • VEGFA expression • CA9 expression"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/20/2017","start_date":" 06/20/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2024-05-15"},{"id":"561428b5-f2b3-4959-8d03-ea3cd30a25f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00892866","created_at":"2021-01-18T03:25:21.231Z","updated_at":"2024-07-02T16:35:06.201Z","phase":"","brief_title":"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells","source_id_and_acronym":"NCT00892866","lead_sponsor":"GOG Foundation","biomarkers":" CA9 • MCM2","pipe":" | ","alterations":" CA9 expression","tags":["CA9 • MCM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 877","initiation":"Initiation: 04/13/2009","start_date":" 04/13/2009","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-03"},{"id":"5f16282f-b255-4864-95a6-951ea5963c93","acronym":"","url":"https://clinicaltrials.gov/study/NCT05818865","created_at":"2023-04-19T19:07:03.089Z","updated_at":"2024-07-02T16:35:12.902Z","phase":"","brief_title":"\"Principle Test\" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.","source_id_and_acronym":"NCT05818865","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" EPCAM • VIM","pipe":" | ","alterations":" CA9 expression","tags":["EPCAM • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 03/22/2022","primary_completion_date":" 03/22/2022","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-26"},{"id":"9616c2d2-5400-434d-9a4a-0bdbdb7663da","acronym":"PERTINENCE","url":"https://clinicaltrials.gov/study/NCT04897763","created_at":"2021-05-24T16:53:38.292Z","updated_at":"2024-07-02T16:35:55.050Z","phase":"Phase 1","brief_title":"Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)","source_id_and_acronym":"NCT04897763 - PERTINENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" CA9","pipe":" | ","alterations":" CA9 expression","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/24/2022","primary_completion_date":" 08/24/2022","study_txt":" Completion: 09/26/2022","study_completion_date":" 09/26/2022","last_update_posted":"2023-02-21"},{"id":"9f6aadae-4c02-4885-9474-ee02d40d74f7","acronym":"OPALESCENCE","url":"https://clinicaltrials.gov/study/NCT04758780","created_at":"2021-02-17T14:01:01.787Z","updated_at":"2024-07-02T16:35:55.082Z","phase":"Phase 2","brief_title":"Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04758780 - OPALESCENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" HER-2 • ER • PGR • CA9","pipe":" | ","alterations":" CA9 expression","tags":["HER-2 • ER • PGR • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-02-21"},{"id":"1bdfa3c5-3480-4494-ac29-f5c50d54ac49","acronym":"","url":"https://clinicaltrials.gov/study/NCT05214885","created_at":"2022-02-05T18:27:39.891Z","updated_at":"2024-07-02T16:36:15.793Z","phase":"","brief_title":"Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT05214885","lead_sponsor":"Qianfoshan Hospital","biomarkers":" CA9 • NDUFA4L2 • EGLN3","pipe":" | ","alterations":" CA9 expression","tags":["CA9 • NDUFA4L2 • EGLN3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/11/2022","start_date":" 02/11/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2022-03-09"},{"id":"59147de9-a288-4465-b490-08d521c36c94","acronym":"ZIRDAC-JP","url":"https://clinicaltrials.gov/study/NCT04496089","created_at":"2021-01-18T21:35:36.413Z","updated_at":"2024-07-02T16:36:25.928Z","phase":"Phase 1","brief_title":"Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC","source_id_and_acronym":"NCT04496089 - ZIRDAC-JP","lead_sponsor":"Telix International Pty Ltd","biomarkers":" CA9","pipe":" | ","alterations":" CA9 expression","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 04/06/2021","study_completion_date":" 04/06/2021","last_update_posted":"2021-08-24"},{"id":"c679c891-db2e-48af-a57b-9b8c26706382","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381797","created_at":"2021-01-18T01:19:39.832Z","updated_at":"2024-07-02T16:37:16.033Z","phase":"Phase 2","brief_title":"Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma","source_id_and_acronym":"NCT00381797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KDR • EPAS1 • CA9","pipe":" | ","alterations":" VEGFA overexpression • VEGFA expression • CA9 expression","tags":["KDR • EPAS1 • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA overexpression • VEGFA expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-11-28"}]